Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)

被引：37
|
作者：
Curigliano, Giuseppe [1 ,2 ]
Hu, Xichun [3 ]
Dent, Rebecca Alexandra [4 ]
Yonemori, Kan [5 ]
Barrios Sr, Carlos H. [6 ]
O'Shaughnessy, Joyce [7 ]
Wildiers, Hans [8 ]
Zhang, Qingyuan [9 ]
Im, Seock-Ah [10 ]
Saura, Cristina [11 ]
Biganzoli, Laura [12 ]
Sohn, Joohyuk [13 ]
Levy, Christelle [14 ]
Jacot, William [15 ]
Begbie, Natasha [16 ]
Ke, Jun [17 ]
Patel, Gargi Surendra [18 ]
Bardia, Aditya
机构：
[1] Univ Milan, Milan, Italy
[2] IRCCS, European Inst Oncol, Milan, Italy
[3] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[4] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[5] Natl Canc Ctr, Tokyo, Japan
[6] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, Brazil
[7] Baylor Univ, US Oncol Network, Texas Oncol, Med Ctr, Dallas, TX USA
[8] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium
[9] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[10] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[11] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[12] Santo Stefano Hosp, Azienda USL Toscana Ctr, Dept Oncol, Prato, Italy
[13] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
[14] Ctr Francois Baclesse, Caen, France
[15] Univ Montpellier, Inst Canc Montpellier, Dept Med Oncol, Montpellier, France
[16] AstraZeneca, Clin Dev, Late Stage Dev, Oncol R&D, Cambridge, England
[17] AstraZeneca, Biometr Oncol, Late Stage Dev, Oncol R&D, Waltham, MA USA
[18] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 17_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.17_suppl.LBA1000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA1000
引用
收藏
页码：LBA1000 / LBA1000
页数：1
相关论文
共 50 条
  • [21] Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09
    Tolaney, S. M.
    Barroso-Sousa, R.
    Jiang, Z.
    Park, Y. H.
    Rimawi, M.
    Manich, C. Saura
    Schneeweiss, A.
    Toi, M.
    Yu, T.
    Shetty, J.
    Herbolsheimer, P.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S507 - S508
  • [22] Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09
    Tolaney, Sara M.
    Barroso-Sousa, Romualdo
    Jiang, Zefei
    Park, Yeon Hee
    Rimawi, Mothaffar
    Saura, Cristina
    Schneeweiss, Andreas
    Toi, Masakazu
    Yu, Tinghui
    Shetty, Jagdish
    Herbolsheimer, Pia
    Loibl, Sibylle
    CANCER RESEARCH, 2022, 82 (04)
  • [23] The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer
    Sudpreeda Chainitikun
    James P. Long
    Ruben Rodriguez-Bautista
    Toshiaki Iwase
    Debu Tripathy
    Takeo Fujii
    Naoto T. Ueno
    Breast Cancer Research and Treatment, 2020, 183 : 729 - 739
  • [24] RIBOCICLIB AND ENDOCRINE THERAPY (ET) IN HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER-2) BREAST CANCER: THE MONALEESA CLINICAL TRIALS PROGRAM
    Campone, Mario
    Tripathy, Debu
    Chia, Stephen
    Diaz-Padilla, Ivan
    Lorenc, Karen R.
    Miller, Michelle
    Germa, Caroline
    Conte, Pierfranco
    BREAST, 2017, 36 : S50 - S50
  • [25] The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer
    Chainitikun, Sudpreeda
    Long, James P.
    Rodriguez-Bautista, Ruben
    Iwase, Toshiaki
    Tripathy, Debu
    Fujii, Takeo
    Ueno, Naoto T.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (03) : 729 - 739
  • [26] Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)
    Curigliano, G.
    Dunton, K.
    Rosenlund, M.
    Janek, M.
    Cathcart, J.
    Liu, Y.
    Fasching, P. A.
    Iwata, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S196 - S197
  • [27] Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[ plus ])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial
    Llombart-Cussac, Antonio
    Harper-Wynne, Catherine
    Perello, Antonia
    Hennequin, Audrey
    Fernandez, Adela
    Colleoni, Marco
    Caranana, Vicente
    Quiroga, Vanesa
    Medioni, Jacques
    Iranzo, Vega
    Wheatley, Duncan
    Del Barco, Sonia
    Anton, Antonio
    Dobi, Erion
    Ruiz-Borrego, Manuel
    Alcala-Lopez, Daniel
    Perez-Escuredo, Jhudit
    Sampayo-Cordero, Miguel
    Perez-Garcia, Jose Manuel
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population
    Salvador, J.
    Ciruelos, E. M.
    Prat, A.
    Jimenez-Rodriguez, B.
    de la Cruz, L.
    Martinez, N.
    Villanueva Vazquez, R.
    de Toro, R.
    Anton, A.
    Moreno, F.
    Alvarez, I.
    Gavila, J.
    Quiroga, V.
    Vicente, E.
    de la Haba, J.
    Gonzalez-Santiago, S.
    Diaz, N.
    Barnadas, A.
    Cantos Sanchez de Ibarguen, B.
    Delgado, J. I.
    Bellet, M.
    Gimeno, A.
    Sanz, S.
    Martin, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [29] Systematic Literature Review of Hormone Receptor (HR) Positive, Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer Patients from India
    Singh, M.
    Pratiksha, K.
    Alam, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S160 - S160
  • [30] Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive (HR+)/HER2 receptor-negative (HER2-) metastatic breast cancer (MBC): A real life multicenter Italian study
    Palumbo, R.
    Torrisi, R.
    Quaquarini, E.
    Sottotetti, F.
    Gambaro, A.
    Collova, E.
    Ferzi, A.
    Fava, S.
    Agostinetto, E.
    Tagliaferri, B.
    Licata, L.
    Teragni, C.
    Bernardo, A.
    CANCER RESEARCH, 2019, 79 (04)
12345